Immunosuppressive therapy in liver transplantation

Slides:

Advertisements

Similar presentations

1 How we prevent infection. 2 Ch Innate Immunity.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD

T. Sternfeld, V. Spöri-Byrtus, C. Riediger, R. Langer, H. Friess, R. M

Inflammasomes in liver diseases

Volume 50, Issue 4, Pages (April 2009)

An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

Transplant Immunology and Immunosuppression: Core Curriculum 2015

Geoffrey W McCaughan, Amany Zekry Journal of Hepatology

Immunotherapy of hepatocellular carcinoma

Autoimmune hepatitis – Update 2015

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD

Pathological roles of purinergic signaling in the liver

The yin and yang of evasion and immune activation in HCC

Reactive oxygen species in the normal and acutely injured liver

Obesity, inflammation, and liver cancer

Geoffrey W McCaughan, Amany Zekry Journal of Hepatology

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Differentiation and Functions of CD8+ Effector T Cells

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders Robert P. Hirten, Marietta Iacucci, Shailja Shah,

Transplantation Immunology

Regulatory T-cell directed therapies in liver diseases

Allogeneic hematopoietic cell transplant in HCV-infected patients

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results Bruno Roche, Didier Samuel Journal.

Living donor liver transplantation: is the hype over?

Transplant Immunology and Immunosuppression: Core Curriculum 2015

Volume 132, Issue 2, Pages (February 2007)

Mesenchymal stromal cell therapy for liver diseases

Cyclosporine in the Treatment of Dermatologic Disease: An Update

T –HELPER CELL AMMAR HADI

Autoimmune hepatitis: A life-long disease

Chronic HCV infection and the clonality of intrahepatic T cells

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD

From immunosuppression to tolerance

Regulatory T-cell directed therapies in liver diseases

Leonardo V. Riella, Mohamed H. Sayegh Kidney International Supplements

Hepatitis C core protein – The “core” of immune deception?

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Targets for immunotherapy of liver cancer

The yin and yang of evasion and immune activation in HCC

Volume 61, Issue 1, Pages S69-S78 (November 2014)

Robert J Korst, MD, Ronald G Crystal, MD

Immune System Practice Test

Interleukin-17 Kick-Starts T Helper 1 Cell Differentiation

Volume 43, Issue 4, Pages (October 2005)

Volume 59, Issue 3, Pages (September 2013)

Volume 44, Issue 4, Pages (April 2006)

Discussion on spontaneous resolution of chronic hepatitis C virus after withdrawal of immunosuppression Ulf Peter Neumann, Peter Neuhaus Gastroenterology

Jonathan H. Esensten, MD, PhD, Yannick D. Muller, MD, PhD, Jeffrey A

Dendritic cells: regulators of hepatic immunity or tolerance?

Transplantation Immunology

S. Tamir Rashid, Graeme J.M. Alexander Journal of Hepatology

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

Volume 63, Issue 2, Pages (August 2015)

Ricardo U. Sorensen, MD, Luke A. Wall, MD

Volume 50, Issue 4, Pages (April 2009)

Immunotherapy for Lung Cancer

Immunosuppression in liver transplant recipients with renal impairment

The use of hemospray in portal hypertensive bleeding; a case series

Liver transplantation in children

Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi

Addition of mycophenolate mofetil to tacrolimus is associated with decreases in food- specific IgE levels in a pediatric patient with liver transplantation-associated.

Pathogenesis of cholestatic hepatitis C

Chimeric mouse model of hepatitis B virus infection

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Volume 163, Issue 4, (November 2015)

Immune pathomechanism of drug hypersensitivity reactions

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Presentation transcript:

Immunosuppressive therapy in liver transplantation Filomena Conti, Emmanuel Morelon, Yvon Calmus Journal of Hepatology Volume 39, Issue 5, Pages 664-678 (November 2003) DOI: 10.1016/S0168-8278(03)00428-8

Fig. 1 Mechanisms of allograft rejection: afferent and efferent limbs of the allogeneic immune response. APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; IL2, interleukin-2; LB, lymphocyte B; LTh, lymphocyte T helper. Journal of Hepatology 2003 39, 664-678DOI: (10.1016/S0168-8278(03)00428-8)

Fig. 2 Targets of immunosuppressive drugs. APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; IL1, interleukin-1; LB, lymphocyte B; MMF, mycophenolate mofetil. Journal of Hepatology 2003 39, 664-678DOI: (10.1016/S0168-8278(03)00428-8)